Simpson Thacher is representing J.P. Morgan Securities LLC, Credit Suisse Securities, Goldman Sachs Bank USA and UBS Securities LLC as joint lead arrangers and joint bookrunners in connection with a portion of the $2.2 billion financing for the $3.9 billion acquisition of Pharmaceutical Product Development, Inc. by affiliates of The Carlyle Group and Hellman & Friedman LLC. The merger is expected to be completed during the fourth quarter of 2011.
Pharmaceutical Product Development, Inc. is a leading global contract research organization providing drug discovery, development and lifecycle management services. Pharmaceutical Product Development, Inc.’s clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, Pharmaceutical Product Development, Inc. applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.
The Simpson Thacher team includes Patrick Ryan, Brian Gluck and Chelsea Freeman (Credit); Art Robinson, Lesley Peng, Ryan Bekkerus, Matt Reichstein and Andrew Wolstan (Capital Markets); Ed Chung (M&A); Michael Isby (Environmental); Paul Koppel and Sarah Dale (Executive Compensation and Employee Benefits); Scott Dyer (Labor); Parijat Sharma (Intellectual Property); and Danny Salinas (Tax).